ArticleInvestigational new drugs2019

Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer.

Masafumi Ikeda et al.PubMed ↗Publisher ↗

No numbers read from the abstract.